Morphine hydrochloride sustained release - Takeda

Drug Profile

Morphine hydrochloride sustained release - Takeda

Alternative Names: TAK 453 SR; TAK-453

Latest Information Update: 11 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Morphine derivatives; Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer pain

Most Recent Events

  • 11 Jun 2015 No recent reports on development identified - Registered for Cancer pain in Japan (PO)
  • 21 Oct 2002 Phase-III clinical trials in Cancer pain management in Japan (PO)
  • 18 Apr 2002 Phase-II clinical trials in Pain in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top